Grassin-Delyle Stanislas, Naline Emmanuel, Devillier Philippe
aLaboratoire de Pharmacologie Respiratoire UPRES EA220, Hôpital Foch, Suresnes bUniversité Versailles Saint-Quentin, UFR Sciences de la Santé Simone Veil, Montigny-Le-Bretonneux, France.
Curr Opin Allergy Clin Immunol. 2015 Feb;15(1):63-9. doi: 10.1097/ACI.0000000000000137.
Although today's cornerstone therapies for asthma (inhaled bronchodilators and corticosteroids) target airway narrowing and lung inflammation, about half of treated asthmatic patients do not achieve good disease control. There is a clear need for new therapeutic approaches and novel drug targets. Recent research has unexpectedly revealed that certain taste receptors (particularly those involved in bitter taste transduction) are expressed in lung tissue.
Bitter taste receptors are expressed in several cell types in the lungs (such as chemosensory cells, epithelial cells, smooth muscle cells, lymphocytes, and macrophages) and variously involved in ciliary beating, muscle relaxation, and/or inhibition of the production of inflammatory mediators. Here, we review recent research on the role of bitter taste receptors in experimental models of asthma and in asthmatics.
The currently available data suggest that bitter taste receptor agonists have therapeutic potential in chronic obstructive airway diseases such as asthma.
尽管当今哮喘的基础治疗方法（吸入性支气管扩张剂和皮质类固醇）针对气道狭窄和肺部炎症，但约一半接受治疗的哮喘患者并未实现良好的疾病控制。显然需要新的治疗方法和新型药物靶点。最近的研究意外发现，某些味觉受体（特别是那些参与苦味转导的受体）在肺组织中表达。
苦味受体在肺中的几种细胞类型中表达（如化学感受细胞、上皮细胞、平滑肌细胞、淋巴细胞和巨噬细胞），并以不同方式参与纤毛摆动、肌肉松弛和/或抑制炎症介质的产生。在此，我们综述了关于苦味受体在哮喘实验模型和哮喘患者中作用的最新研究。
目前可得的数据表明，苦味受体激动剂在诸如哮喘等慢性阻塞性气道疾病中具有治疗潜力。
